Invion spin-off chooses R&G Pharma for COPD research

Company News

by Rachael Jones

Chronic Airway Therapeutics, a proposed spin-off from Invion (ASX:IVX) has selected leading Chinese contract research organisation R&G Pharma Studies Co to support the development in China of nadolol as a treatment for chronic obstructive pulmonary disease (COPD).

R&G is one of China’s leading Contract Research Organisations.

CAT selected R&G because of the company’s demonstrated expertise, strong relationships with the China Food and Drug Administration (CFDA), and deep understanding of the similarities and differences with US FDA regulations.

Nadolol, which – unlike existing treatments – can be administered in one single tablet per day, could play an integral role in diminishing the impact of COPD.

Shares in Invion (ASX:IVX) closed flat at 3.6 cents yesterday.
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.